Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer

Journal of Clinical Oncology

Volumn 32, Issue 35, 2014, Pages 3939-3947

  Abdollah, Firas ^a   Karnes, R Jeffrey ^b   Suardi, Nazareno ^c   Cozzarini, Cesare ^c   Gandaglia, Giorgio ^c   Fossati, Nicola ^c   Vizziello, Damiano ^c   Sun, Maxine ^d   Karakiewicz, Pierre I ^d   Menon, Mani ^a   Montorsi, Francesco ^c   Briganti, Alberto ^c  

^a HENRY FORD HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PROSTATE CANCER; PROSTATECTOMY; TERTIARY CARE CENTER; ADJUVANT THERAPY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME; TUMOR INVASION;

AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 84918510383     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.7893     Document Type: Article

References (18)

1. Boorjian SA, Thompson RH, Siddiqui S, et al: Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864-870, 2007
2. Briganti A, Karnes JR, Da Pozzo LF, et al: Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer: A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55:261-270, 2009
3. Cheng L, Zincke H, Blute ML, et al: Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91:66-73, 2001
4. Da Pozzo LF, Cozzarini C, Briganti A, et al: Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: The positive impact of adjuvant radiotherapy. Eur Urol 55:1003-1011, 2009
5. Daneshmand S, Quek ML, Stein JP, et al: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 172:2252-2255, 2004
6. Schumacher MC, Burkhard FC, Thalmann GN, et al: Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54:344-352, 2008
7. von Bodman C, Godoy G, Chade DC, et al: Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 184:143-148, 2010
8. Abdollah F, Suardi N, Gallina A, et al: Extended pelvic lymph node dissection in prostate cancer: A 20-year audit in a single center. Ann Oncol 24:1459-1466, 2013
9. Abdollah F, Sun M, Thuret R, et al: Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. Eur Urol 58:882-892, 2010
10. Briganti A, Passoni NM, Abdollah F, et al: Treatment of lymph node-positive prostate cancer: Teaching old dogmas new tricks. Eur Urol 65:26-27, 2014
11. Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006
12. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
13. Touijer KA, Mazzola CR, Sjoberg DD, et al: Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65:20-25, 2014
14. Abdollah F, Suardi N, Cozzarini C, et al: Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: A long-term survival analysis. Eur Urol 63:998-1008, 2013
15. Briganti A, Karnes RJ, Da Pozzo LF, et al: Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: Results of a matched analysis. Eur Urol 59:832-840, 2011
16. Shukla ME, Reddy CA, Stephans KL, et al: Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy. J Clin Oncol 30, 2012 (suppl 5; abstr 195)
17. Cozzarini C, Montorsi F, Fiorino C, et al: Need for high radiation dose (> or = 70 gy) in early postoperative irradiation after radical prostatectomy: A single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 75:966-974, 2009
18. Segal MR: Regression trees for censored data. Biometrics 44:35-47, 1988